Eisai and Biogen are one step away from deploying a more convenient version of their jointly developed Alzheimer’s treatment ...

FDA sets August 31, 2025, as the action date for Eisai and Biogen's Leqembi subcutaneous autoinjector application. Leqembi's ...

GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase ...

The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...

To date, Leqembi has been approved in the US, Japan, China, South Korea, Hong Kong, Israel, UAE, GB, Mexico, and Macau, and ...

The FDA has accepted Eisai and Biogen’s biologics license application for a monthly infusion of IV Leqembi to treat ...

Biogen Inc. (BIIB), headquartered in Cambridge, Massachusetts, specializes in discovering, developing, manufacturing, and ...

Leqembi is not known to interact with alcohol, other drugs, or supplements. However, the drug has some health-related interactions. Talk with your doctor to avoid potentially harmful effects from ...

Eisai (ESAIY) and Biogen (BIIB) announced that the FDA has accepted Eisai’s Biologics License Application, BLA, for ...

"The view out there in the analyst community is that the future of Biogen depends on the next deal that we do and that's not ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

In a report released yesterday, Evan Seigerman from BMO Capital maintained a Hold rating on Biogen (BIIB – Research Report), with a price ...